Macrogenics Inc Financials

MGNX

Export CSV

Key Financial Metrics

Revenue

$150.0M

YoY+155.3%

5Y CAGR+18.5%

10Y CAGR+12.1%

Macrogenics Inc generated $150.0M in revenue in fiscal year 2024. This represents an increase of 155.3% from the prior year.

EBITDA

-$103.0M

YoY+35.0%

Macrogenics Inc's EBITDA was -$103.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 35.0% from the prior year.

Free Cash Flow

-$72.1M

YoY+9.9%

Macrogenics Inc generated -$72.1M in free cash flow in fiscal year 2024, representing cash available after capital expenditures. This represents an increase of 9.9% from the prior year.

Net Income

-$67.0M

YoY-639.3%

Macrogenics Inc reported -$67.0M in net income in fiscal year 2024. This represents a decrease of 639.3% from the prior year.

EPS (Diluted)

$-1.07

YoY-613.3%

Macrogenics Inc earned $-1.07 per diluted share in fiscal year 2024. This represents a decrease of 613.3% from the prior year.

Cash & Debt

$182.8M

YoY+81.1%

5Y CAGR+7.7%

10Y CAGR+1.5%

Macrogenics Inc held $182.8M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

63M

YoY+1.2%

5Y CAGR+5.1%

10Y CAGR+8.4%

Macrogenics Inc had 63M shares outstanding in fiscal year 2024. This represents an increase of 1.2% from the prior year.

Gross Margin

99.4%

YoY+0.5pp

5Y CAGR-0.6pp

Macrogenics Inc's gross margin was 99.4% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 0.5 percentage points from the prior year.

Operating Margin

-73.7%

YoY+212.6pp

5Y CAGR+202.3pp

10Y CAGR+6.4pp

Macrogenics Inc's operating margin was -73.7% in fiscal year 2024, reflecting core business profitability. This is up 212.6 percentage points from the prior year.

Net Margin

-44.7%

YoY-29.2pp

5Y CAGR+191.8pp

10Y CAGR+35.5pp

Macrogenics Inc's net profit margin was -44.7% in fiscal year 2024, showing the share of revenue converted to profit. This is down 29.2 percentage points from the prior year.

Return on Equity

N/A

R&D Spending

$177.2M

YoY+6.4%

5Y CAGR-1.9%

10Y CAGR+9.7%

Macrogenics Inc invested $177.2M in research and development in fiscal year 2024. This represents an increase of 6.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$3.7M

YoY+110.1%

5Y CAGR-2.9%

10Y CAGR+0.4%

Macrogenics Inc invested $3.7M in capital expenditures in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 110.1% from the prior year.

MGNX Income Statement

Metric	FY24	FY24	FY24	FY23	FY22	FY21
Revenue	$150.0M+155.3%	$58.7M-61.3%	$151.9M+96.2%	$77.4M-26.2%	$104.9M+63.4%	$64.2M
Cost of Revenue	$847K+36.8%	$619K-81.5%	$3.4M+26.4%	$2.7M	$0	$0
Gross Profit	$149.1M+156.5%	$58.1M-60.9%	$148.6M+98.7%	$74.8M-28.7%	$104.9M+63.4%	$64.2M
R&D Expenses	$177.2M+6.4%	$166.6M-19.5%	$207.0M-3.5%	$214.6M+11.1%	$193.2M-1.1%	$195.3M
SG&A Expenses	$71.0M+36.1%	$52.2M-11.5%	$58.9M-6.5%	$63.0M+47.4%	$42.7M-7.2%	$46.1M
Operating Income	-$110.6M+34.3%	-$168.2M-38.6%	-$121.4M+40.1%	-$202.8M-54.7%	-$131.1M+26.0%	-$177.2M
Interest Expense	$1.1M-22.0%	$1.4M	$0	$0	N/A	N/A
Income Tax	$944K	$0	$0	$0	$0	$0
Net Income	-$67.0M-639.3%	-$9.1M+92.4%	-$119.8M+40.7%	-$202.1M-55.8%	-$129.7M+14.5%	-$151.8M
EPS (Diluted)	$-1.07-613.3%	$-0.15+92.3%	$-1.95+42.1%	$-3.37-36.4%	$-2.47+21.8%	$-3.16

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Revenue	$72.8M+227.5%	$22.2M+68.6%	$13.2M	N/A	$110.7M+925.4%	$10.8M+18.6%	$9.1M	N/A
Cost of Revenue	$0	$0	$0	N/A	$168K-4.5%	$176K-34.8%	$270K	N/A
Gross Profit	$72.8M+227.5%	$22.2M+68.6%	$13.2M	N/A	$110.5M+940.8%	$10.6M+20.2%	$8.8M	N/A
R&D Expenses	$32.7M-19.8%	$40.8M+2.8%	$39.7M	N/A	$40.5M-21.6%	$51.7M+12.4%	$46.0M	N/A
SG&A Expenses	$9.9M+6.5%	$9.3M-13.2%	$10.7M	N/A	$14.1M-2.2%	$14.4M-1.9%	$14.7M	N/A
Operating Income	$18.6M+150.7%	-$36.8M+13.8%	-$42.6M	N/A	$54.2M+193.1%	-$58.2M-8.2%	-$53.8M	N/A
Interest Expense	$3.3M+316.7%	$802K+781.3%	$91K	N/A	$0-100.0%	$6K-99.5%	$1.1M	N/A
Income Tax	$0-100.0%	$105K	N/A	N/A	$0	$0	N/A	N/A
Net Income	$16.8M+146.4%	-$36.3M+11.7%	-$41.0M	N/A	$56.3M+201.2%	-$55.7M-6.7%	-$52.2M	N/A
EPS (Diluted)	$0.27+147.4%	$-0.57+12.3%	$-0.65	N/A	$0.90+201.1%	$-0.89-6.0%	$-0.84	N/A

MGNX Balance Sheet

Metric	FY24	FY24	FY24	FY23	FY22	FY21
Total Assets	$261.7M-12.3%	$298.4M+6.4%	$280.5M-16.3%	$335.2M-11.5%	$378.7M+21.2%	$312.5M
Current Assets	$217.5M-13.5%	$251.3M+13.1%	$222.2M-20.5%	$279.6M-10.6%	$312.6M+30.4%	$239.8M
Cash & Equivalents	$182.8M+81.1%	$101.0M-7.3%	$108.9M-11.8%	$123.5M-31.8%	$181.1M+43.2%	$126.5M
Inventory	$0-100.0%	$1.2M-15.9%	$1.5M-66.9%	$4.4M	$0	N/A
Accounts Receivable	$4.3M-58.4%	$10.4M-81.6%	$56.2M+441.3%	$10.4M-55.0%	$23.1M+81.1%	$12.7M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$145.6M-0.1%	$145.8M+5.3%	$138.5M+44.8%	$95.6M+15.4%	$82.9M+1.2%	$81.9M
Current Liabilities	$55.5M-1.0%	$56.1M+15.4%	$48.6M-34.8%	$74.6M+47.2%	$50.7M+12.2%	$45.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$116.1M-24.0%	$152.6M+7.5%	$142.0M-40.7%	$239.6M-19.0%	$295.9M+28.3%	$230.6M
Retained Earnings	-$1.2B-6.1%	-$1.1B-0.8%	-$1.1B-12.3%	-$973.9M-26.2%	-$771.8M-20.2%	-$642.1M

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Total Assets	$270.8M+10.3%	$245.4M+9.3%	$224.6M-14.2%	$261.7M-1.1%	$264.5M+31.5%	$201.1M-19.0%	$248.3M-16.8%	$298.4M
Current Assets	$232.1M+13.2%	$204.9M+12.6%	$182.1M-16.3%	$217.5M-2.1%	$222.2M+41.6%	$157.0M-22.5%	$202.6M-19.4%	$251.3M
Cash & Equivalents	$80.1M-38.7%	$130.7M-10.2%	$145.6M-20.4%	$182.8M+1.8%	$179.6M+114.0%	$83.9M+4.5%	$80.4M-20.4%	$101.0M
Inventory	$8.8M-5.7%	$9.3M-1.6%	$9.4M	$0-100.0%	$3.2M+190.9%	$1.1M-10.7%	$1.2M+2.2%	$1.2M
Accounts Receivable	$69.2M+452.4%	$12.5M+18.9%	$10.5M+144.7%	$4.3M-50.8%	$8.8M+41.3%	$6.2M-14.2%	$7.2M-30.4%	$10.4M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$203.8M+2.5%	$198.8M+36.7%	$145.4M-0.1%	$145.6M+0.8%	$144.4M+0.8%	$143.3M+0.8%	$142.1M-2.5%	$145.8M
Current Liabilities	$44.5M+14.0%	$39.0M-29.7%	$55.4M-0.2%	$55.5M-6.4%	$59.3M+2.4%	$57.9M+3.8%	$55.8M-0.6%	$56.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$67.0M+43.7%	$46.6M-41.1%	$79.1M-31.8%	$116.1M-3.3%	$120.1M+107.7%	$57.8M-45.5%	$106.2M-30.4%	$152.6M
Retained Earnings	-$1.2B+1.3%	-$1.2B-3.0%	-$1.2B-3.5%	-$1.2B-1.3%	-$1.2B+4.7%	-$1.2B-4.8%	-$1.2B-4.7%	-$1.1B

MGNX Cash Flow Statement

Metric	FY24	FY24	FY24	FY23	FY22	FY21
Operating Cash Flow	-$68.4M+12.6%	-$78.2M+10.1%	-$87.0M+39.5%	-$143.8M-28.5%	-$111.9M+16.7%	-$134.3M
Capital Expenditures	$3.7M+110.1%	$1.8M-51.3%	$3.6M-41.6%	$6.2M+5.0%	$5.9M+37.7%	$4.3M
Free Cash Flow	-$72.1M+9.9%	-$80.0M+11.7%	-$90.6M+39.6%	-$150.0M-27.4%	-$117.8M+15.0%	-$138.6M
Investing Cash Flow	$149.3M+286.4%	-$80.1M-213.2%	$70.7M+293.2%	-$36.6M-370.3%	-$7.8M+90.2%	-$79.4M
Financing Cash Flow	$960K-99.4%	$150.4M+8963.4%	$1.7M-98.6%	$122.8M-29.6%	$174.3M+45.3%	$120.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Operating Cash Flow	N/A	N/A	-$46.9M	N/A	N/A	N/A	-$45.6M	N/A
Capital Expenditures	N/A	N/A	$529K	N/A	N/A	N/A	$1.5M	N/A
Free Cash Flow	N/A	N/A	-$47.4M	N/A	N/A	N/A	-$47.1M	N/A
Investing Cash Flow	N/A	N/A	$9.9M	N/A	N/A	N/A	$24.8M	N/A
Financing Cash Flow	N/A	N/A	-$282K	N/A	N/A	N/A	$248K	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

MGNX Financial Ratios

Metric	FY24	FY24	FY24	FY23	FY22	FY21
Gross Margin	99.4%+0.5pp	99.0%+1.2pp	97.8%+1.2pp	96.6%-3.4pp	100.0%0.0pp	100.0%
Operating Margin	-73.7%+212.6pp	-286.4%-206.5pp	-79.9%+181.9pp	-261.9%-136.9pp	-125.0%+151.1pp	-276.0%
Net Margin	-44.7%-29.2pp	-15.4%+63.4pp	-78.8%+182.2pp	-261.0%-137.3pp	-123.7%+112.8pp	-236.5%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-25.6%-22.6pp	-3.0%+39.7pp	-42.7%+17.6pp	-60.3%-26.0pp	-34.3%+14.3pp	-48.6%
Current Ratio	3.92-0.6	4.48-0.1	4.57+0.8	3.75-2.4	6.17+0.9	5.31
Debt-to-Equity	1.25+0.3	0.96-0.0	0.97+0.6	0.40+0.1	0.28-0.1	0.35
FCF Margin	-48.1%+88.1pp	-136.1%-76.5pp	-59.6%+134.1pp	-193.7%-81.4pp	-112.3%+103.5pp	-215.9%

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Gross Margin	100.0%0.0pp	100.0%0.0pp	100.0%	N/A	99.9%+1.5pp	98.4%+1.3pp	97.0%	N/A
Operating Margin	25.6%+190.9pp	-165.3%+157.8pp	-323.1%	N/A	48.9%+587.8pp	-538.9%+51.5pp	-590.4%	N/A
Net Margin	23.1%+186.1pp	-163.0%+148.1pp	-311.1%	N/A	50.9%+566.4pp	-515.5%+57.7pp	-573.3%	N/A
Return on Equity	25.1%	N/A	N/A	N/A	46.9%	N/A	N/A	N/A
Return on Assets	6.2%+21.0pp	-14.8%+3.5pp	-18.3%	N/A	21.3%+49.0pp	-27.7%-6.7pp	-21.0%	N/A
Current Ratio	5.22-0.0	5.25+2.0	3.28-0.6	3.92+0.2	3.75+1.0	2.71-0.9	3.63-0.8	4.48
Debt-to-Equity	3.04-1.2	4.26+2.4	1.84+0.6	1.25+0.1	1.20-1.3	2.48+1.1	1.34+0.4	0.96
FCF Margin	N/A	N/A	-359.4%	N/A	N/A	N/A	-517.4%	N/A

Frequently Asked Questions

What is Macrogenics Inc's annual revenue?

Macrogenics Inc (MGNX) reported $150.0M in revenue for fiscal year 2024.

How fast is Macrogenics Inc's revenue growing?

Macrogenics Inc (MGNX) revenue grew by 155.3% year-over-year, from $58.7M to $150.0M in fiscal year 2024.

Is Macrogenics Inc profitable?

No, Macrogenics Inc (MGNX) reported a net income of -$67.0M in fiscal year 2024, with a net profit margin of -44.7%.

What is Macrogenics Inc's earnings per share (EPS)?

Macrogenics Inc (MGNX) reported diluted earnings per share of $-1.07 for fiscal year 2024.

What is Macrogenics Inc's EBITDA?

Macrogenics Inc (MGNX) had EBITDA of -$103.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Macrogenics Inc's gross margin?

Macrogenics Inc (MGNX) had a gross margin of 99.4% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

What is Macrogenics Inc's operating margin?

Macrogenics Inc (MGNX) had an operating margin of -73.7% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Macrogenics Inc's net profit margin?

Macrogenics Inc (MGNX) had a net profit margin of -44.7% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Macrogenics Inc's free cash flow?

Macrogenics Inc (MGNX) generated -$72.1M in free cash flow during fiscal year 2024, representing cash available after capital expenditures.

What is Macrogenics Inc's operating cash flow?

Macrogenics Inc (MGNX) generated -$68.4M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Macrogenics Inc's total assets?

Macrogenics Inc (MGNX) had $261.7M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Macrogenics Inc's capital expenditures?

Macrogenics Inc (MGNX) invested $3.7M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Macrogenics Inc spend on research and development?

Macrogenics Inc (MGNX) invested $177.2M in research and development during fiscal year 2024.

How many shares does Macrogenics Inc have outstanding?

Macrogenics Inc (MGNX) had 63M shares outstanding as of fiscal year 2024.

What is Macrogenics Inc's current ratio?

Macrogenics Inc (MGNX) had a current ratio of 3.92 as of fiscal year 2024, which is generally considered healthy.

What is Macrogenics Inc's debt-to-equity ratio?

Macrogenics Inc (MGNX) had a debt-to-equity ratio of 1.25 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Macrogenics Inc's return on assets (ROA)?

Macrogenics Inc (MGNX) had a return on assets of -25.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.